PDS Biotechnology Corporation

NASDAQ: PDSB · Healthcare · Biotechnology

PublicHQ Princeton, NJ · MercerCIK 0001472091Reports USD

#1 of 1,417 Healthcare companies by revenue

EA Score

——

FH 24DQ —GM —SS 45

v0.1 · 35/100 weight · pillars only

↑ listing tenure, market scale · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$34.5M

Employees

as of 2026-08-19

Market cap

$11.6M

as of 2026-08-19

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$34.5M-$34.5M2025

Operating income-$31.5M-$31.5M2025

Total assets$30.5M$30.5M2025

Liabilities$21.2M$21.2M2025

Equity$9.3M$9.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is PDS Biotechnology Corporation’s financial profile?

PDS Biotechnology Corporation earned -$34.5M in FY2025 net income.

Peers · Healthcare

IN8bio, Inc.——Brainstorm Cell Therapeutics Inc.——Jasper Therapeutics, Inc.——Conavi Medical Corp.——Advanced Biomed Inc. Common Stock——Medicure Inc.——

Neighbors

Mercer →

Bristol-Myers Squibb Company$48.2B85A Essential Properties Realty Trust, Inc.$561.2M71B Clearway Energy, Inc.$1.4B55C Miami International Holdings, Inc. $1.4B43D UroGen Pharma Ltd.$109.8M55C Kardigan, Inc.$0——

Key facts

CEOFrank K. Bedu-Addo

SectorHealthcare

IndustryBiotechnology

HeadquartersPrinceton, NJ

ExchangeNASDAQ: PDSB

Employees21

IPO date2015-09-30

Latest filings

8-K2026-08-19 8-K2026-08-14 10-Q2026-08-13 8-K2026-08-13 8-K2026-08-11 8-K2026-07-31 DEF 14A2026-06-26 8-K2026-06-15

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.